Cargando…

Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives

Keloids are pathological scars presenting as nodular lesions that extend beyond the area of injury. They do not spontaneously regress, often continuing to grow over time. The abnormal wound-healing process underlying keloid formation results from the lack of control mechanisms self-regulating cell p...

Descripción completa

Detalles Bibliográficos
Autores principales: Morelli Coppola, Marco, Salzillo, Rosa, Segreto, Francesco, Persichetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063260/
https://www.ncbi.nlm.nih.gov/pubmed/30087573
http://dx.doi.org/10.2147/CCID.S133672
_version_ 1783342522910638080
author Morelli Coppola, Marco
Salzillo, Rosa
Segreto, Francesco
Persichetti, Paolo
author_facet Morelli Coppola, Marco
Salzillo, Rosa
Segreto, Francesco
Persichetti, Paolo
author_sort Morelli Coppola, Marco
collection PubMed
description Keloids are pathological scars presenting as nodular lesions that extend beyond the area of injury. They do not spontaneously regress, often continuing to grow over time. The abnormal wound-healing process underlying keloid formation results from the lack of control mechanisms self-regulating cell proliferation and tissue repair. Keloids may lead to cosmetic disfigurement and functional impairment and affect the quality of life. Although several treatments were reported in the literature, no universally effective therapy was found to date. The most common approach is intralesional corticosteroid injection alone or in combination with other treatment modalities. Triamcinolone acetonide (TAC) is the most commonly used intralesional corticosteroid. The aim of this article was to review the use of TAC, alone or in combination, in the treatment of keloid scars. The response to corticosteroid injection alone is variable with 50–100% regression and a recurrence rate of 33% and 50% after 1 and 5 years, respectively. Compared to verapamil, TAC showed a faster and more effective response even though with a higher complication rate. TAC combined with verapamil was proved to be effective with statistically significant overall improvements of scars over time and long-term stable results. TAC and 5-fluorouracil (5-FU) intralesional injections were found to achieve comparable outcomes when administered alone, although 5-FU was more frequently associated with side effects. Conversely, the combination of 5-FU and TAC was more effective and showed fewer undesirable effects compared to TAC or 5-FU alone. Several kinds of laser treatments were reported to address keloids; however, laser therapy alone was burdened with a high recurrence rate. Better results were described by combining CO(2), pulsed-dye or Nd: YAG lasers with TAC intralesional injections. Further options such as needle-less intraepidermal drug delivery are being explored, but more studies are needed to establish safety, feasibility and effectiveness of this approach.
format Online
Article
Text
id pubmed-6063260
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60632602018-08-07 Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives Morelli Coppola, Marco Salzillo, Rosa Segreto, Francesco Persichetti, Paolo Clin Cosmet Investig Dermatol Review Keloids are pathological scars presenting as nodular lesions that extend beyond the area of injury. They do not spontaneously regress, often continuing to grow over time. The abnormal wound-healing process underlying keloid formation results from the lack of control mechanisms self-regulating cell proliferation and tissue repair. Keloids may lead to cosmetic disfigurement and functional impairment and affect the quality of life. Although several treatments were reported in the literature, no universally effective therapy was found to date. The most common approach is intralesional corticosteroid injection alone or in combination with other treatment modalities. Triamcinolone acetonide (TAC) is the most commonly used intralesional corticosteroid. The aim of this article was to review the use of TAC, alone or in combination, in the treatment of keloid scars. The response to corticosteroid injection alone is variable with 50–100% regression and a recurrence rate of 33% and 50% after 1 and 5 years, respectively. Compared to verapamil, TAC showed a faster and more effective response even though with a higher complication rate. TAC combined with verapamil was proved to be effective with statistically significant overall improvements of scars over time and long-term stable results. TAC and 5-fluorouracil (5-FU) intralesional injections were found to achieve comparable outcomes when administered alone, although 5-FU was more frequently associated with side effects. Conversely, the combination of 5-FU and TAC was more effective and showed fewer undesirable effects compared to TAC or 5-FU alone. Several kinds of laser treatments were reported to address keloids; however, laser therapy alone was burdened with a high recurrence rate. Better results were described by combining CO(2), pulsed-dye or Nd: YAG lasers with TAC intralesional injections. Further options such as needle-less intraepidermal drug delivery are being explored, but more studies are needed to establish safety, feasibility and effectiveness of this approach. Dove Medical Press 2018-07-24 /pmc/articles/PMC6063260/ /pubmed/30087573 http://dx.doi.org/10.2147/CCID.S133672 Text en © 2018 Morelli Coppola et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Morelli Coppola, Marco
Salzillo, Rosa
Segreto, Francesco
Persichetti, Paolo
Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives
title Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives
title_full Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives
title_fullStr Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives
title_full_unstemmed Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives
title_short Triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives
title_sort triamcinolone acetonide intralesional injection for the treatment of keloid scars: patient selection and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063260/
https://www.ncbi.nlm.nih.gov/pubmed/30087573
http://dx.doi.org/10.2147/CCID.S133672
work_keys_str_mv AT morellicoppolamarco triamcinoloneacetonideintralesionalinjectionforthetreatmentofkeloidscarspatientselectionandperspectives
AT salzillorosa triamcinoloneacetonideintralesionalinjectionforthetreatmentofkeloidscarspatientselectionandperspectives
AT segretofrancesco triamcinoloneacetonideintralesionalinjectionforthetreatmentofkeloidscarspatientselectionandperspectives
AT persichettipaolo triamcinoloneacetonideintralesionalinjectionforthetreatmentofkeloidscarspatientselectionandperspectives